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Background: Recent studies have indicated that the expression of endothelin A receptor (ETAR) and chemokine
receptor 4 (CXCR4) could be used as an indicator of the metastatic potential of nasopharyngeal carcinoma (NPC).
The aim of this study was to determine the prognostic value of ETAR and CXCR4 in NPC patients and to reveal the
interplay of the endothelin-1 (ET-1)/ETAR and stromal-derived factor-1(SDF-1)/CXCR4 pathways in promoting NPC
cell motility.
Methods: Survival analysis was used to analyze the prognostic value of ETAR and CXCR4 expression in 153 cases of
NPC. Chemotaxis assays were used to evaluate alterations in the migration ability of non-metastatic 6-10B and
metastatic 5-8F NPC cells. Real-time PCR, immunoblotting, and flow cytometric analyses were used to evaluate
changes in the expression levels of CXCR4 mRNA and protein induced by ET-1.
Results: The expression levels of ETAR and CXCR4 were closely related to each other and both correlated with a
poor prognosis. A multivariate analysis showed that the expression levels of both ETAR and CXCR4 were
independent prognostic factors for overall survival (OS), progression-free survival (PFS), and distant metastasis-free
survival (DMFS). The migration of 6-10B and 5-8F cells was elevated by ET-1 in combination with SDF-1α. The
knockdown of ETAR protein expression by siRNA reduced CXCR4 protein expression in addition to ETAR protein
expression, leading to a decrease in the metastatic potential of the 5-8F cells. ET-1 induced CXCR4 mRNA and
protein expression in the 6-10B NPC cells in a time- and concentration-dependent fashion and was inhibited by an
ETAR antagonist and PI3K/AKT/mTOR and MAPK/ERK1/2 pathway inhibitors.
Conclusions: ETAR and CXCR4 expression levels are potential prognostic biomarkers in NPC patients. ETAR
activation partially promoted NPC cell migration via a mechanism that enhanced functional CXCR4 expression.
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Nasopharyngeal carcinoma (NPC) is most prevalent in
southern China and Southeast Asia, regions where the
incidence rate of NPC is 25–50 per 100,000 people
[1-3]; by comparison, the incidence is less than 1 per
100,000 in North America and other Western countries
[2]. NPC is notorious for its potential to metastasize via
both lymph and blood vessels during the early stages of
the disease [4]. Although the cervical lymph nodes are
the primary sites of NPC metastasis [5], a considerable
proportion of patients will develop distant metastases to
the bone, lung, and liver [6], and distant metastasis after
treatment is the major cause of treatment failure [7].
Moreover, the mechanisms that control NPC metastasis
remain poorly understood.
Recent studies have revealed that the endothelin-1
(ET-1)/endothelin A receptor (ETAR) axis is related to
the prognosis of cancer patients. Indeed, the serum ET-1
level was correlated with distant metastasis in NPC pa-
tients [8], and the ETAR inhibitor ABT-627 was found
to inhibit the experimental metastasis of NPC cells [9].
The engagement of ETAR by ET-1 triggers the activation
of tumor proliferation [10-14], vascular endothelial
growth factor (VEGF)-induced angiogenesis [15,16], in-
vasiveness [17], and the inhibition of apoptosis [18,19].
The autocrine ET-1/ETAR pathway has a key role in the
development and progression of prostate [10], cervical
[12], and ovarian [13] cancers. These findings support a
role for the ETAR pathway in tumorigenesis and tumor
progression. Furthermore, data from in vitro and in vivo
studies have demonstrated that ETAR is a potential
antitumor target [12].
The metastasis of cancer cells is a complex, highly or-
ganized, non-random, and organ-selective process. A
complex network of chemokines and their receptors in-
fluence the development of primary tumors and metas-
tases [20-23]. Recent studies have clearly demonstrated
the importance of chemokine receptor (CR) expression
in metastasis to specific organs (e.g., lymph nodes, bone
marrow, liver, and lungs) by breast cancer [23], melan-
oma [24], and gastric carcinoma [25] cells. SDF-1
(CXCL12) and its receptor, chemokine receptor 4
(CXCR4), play an important role in tumor cell prolifera-
tion, migration, adhesion, extracellular matrix degrad-
ation, angiogenesis, and immune tolerance induction
[26], and CXCR4 expression is associated with a poor
overall survival (OS) in NPC patients [27]. Additionally,
the expression of functional CXCR4 is associated with
the metastatic potential of human NPC cells [28].
Both ETAR and CXCR4 expression can affect the
metastatic capability of NPC cells. However, the relation-
ship between ETAR and CXCR4 expression remains un-
clear, and the interplay of the ET-1/ETAR and SDF-1/CXCR4
pathways is unknown. A report by Masumi Akimotoet al. [29] showed that the expression levels of CXCR4
and ETAR are both increased in the healing and scar-
ring stages of gastric ulcers, and these receptors have
therefore been suggested to play a role in vascular mat-
uration and gastric mucosal regeneration during late
angiogenesis. In the present study, we investigated the
relationship between ETAR and CXCR4 expression in
NPC tissue and an NPC cell line. We found that ETAR
and CXCR4 were closely related to each other and were
related to the development of distant metastasis and a
poor patient prognosis. We further investigated whether
ETAR activation could increase functional CXCR4 expres-
sion in human NPC cells (6-10B and 5-8F). Our experi-
mental study showed that ET-1 promotes the expression
of functional CXCR4 in non-metastatic human NPC 6-
10B cells and metastatic 5-8F cells and increases the mi-




Between February 1999 and October 2000, 153 consecu-
tive patients with non-metastatic NPC, who were hospital-
ized in the Department of NPC, Sun Yat-sen University
Cancer Center, were enrolled in this study. All patients
had biopsy-proven World Health Organization (WHO)
type III NPC, which is an undifferentiated, non-
keratinizing carcinoma. The study was approved by the
Clinical Research Ethics Committee of the Sun Yat-sen
University Cancer Center, and written informed consent
was obtained from all patients. The AJCC 1997 staging
system was used for clinical staging. All the recruited pa-
tients were treated with a uniform radiotherapy protocol,
as described previously [30]. After completion of the treat-
ment, the patients were followed up at least every
3 months during the first 3 years and then every 6 months
thereafter until death. The patient follow-up was
performed until February 2012. The median duration of
follow-up for the entire group was 83.3 months (range of
3.4-148 months). The patients and clinicopathological
characteristics are described in Table 1.
Immunohistochemical analysis
Tumor specimens from the 153 patients were obtained
by a pretreatment nasopharyngeal biopsy. The speci-
mens were fixed in 10% formalin and embedded in par-
affin, and immunohistochemical staining of these
samples was performed as previously described [8,9].
Briefly, 4-μm-thick tissue sections were deparaffinized
with xylene and rehydrated in a graded series of ethanol.
The endogenous peroxidase activity was blocked with
3% hydrogen peroxide, and the sections were then
subjected to antigen retrieval in a microwave oven using
a citrate buffer solution. After blocking with normal goat
Table 1 Correlation of ETAR/CXCR4 expression with prognostic factors in patients with nasopharyngeal carcinoma
Entire group CXCR4 expression ETAR expression
(n = 153) n (No.%) n (No.%)
Characteristic Positive Negative P value Positive Negative P value
All patients 153 48(31.4) 105(68.6) 113(73.9) 40(26.1)
Mean follow-up, months 83.27 62.77 92.64 79.81 93.05
Age, years 0.049 0.741
≤50 100(65.4) 26(26.0) 74(74.0) 73(73.0) 27(27.0)
>50 53(34.6) 22(41.6) 31(58.4) 40(75.5) 13(24.5)
Sex 0.27 0.213
Male 111(72.5) 32(28.8) 79(71.2) 85(76.6) 26(23.4)
Female 42(27.5) 16(38.1) 26(61.9) 28(66.7) 14(33.3)
T classificationa 0.098 0.517
T1-2 66(43.1) 16(24.2) 50(75.8) 47(71.2) 19(28.8)
T3-4 87(56.9) 32(36.8) 55(63.2) 66(75.9) 21(24.1)
N classificationa 0.681 0.284
N0 32(20.9) 11(34.4) 21(65.6) 26(81.3) 6(19.7)
N1-N3 121(79.1) 37(30.6) 84(69.4) 87(71.9) 34(29.1)
Overall stagea 0.376 0.94
I-II 49(32.0) 13(26.5) 36(73.5) 36(73.5) 13(26.5)
III-IV 104(68.0) 35(33.7) 69(66.3) 77(74.0) 27(26.0)
Chemotherapy 0.394 0.362
Yes 47(30.7) 17(36.2) 30(63.8) 37(78.7) 10(21.3)
No 106(69.3) 31(29.2) 75(70.8) 76(71.7) 30(28.3)
Note: All patients were classified with World Health Organization (WHO) type III NPC.
aUICC 1997 staging system.
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a polyclonal rabbit anti-ETAR antibody (1:100 dilution;
Santa Cruz) or a monoclonal mouse anti-CXCR4 anti-
body (MAB 172; dilution 1:600; R&D Systems) at 4°C
overnight. The sections were then incubated with a
biotin-labeled secondary antibody and streptavidin-
peroxidase for 30 minutes each (Zhongshan Biotechnol-
ogy, Beijing, China). Antibody binding was visualized
using a freshly prepared solution of 0.04% 3′, 3′-
diaminobenzidine tetrahydrochloride and 0.03% hydro-
gen peroxide and then counterstained with hematoxylin;
the samples were then cleaned and mounted. The nega-
tive controls were stained similarly, except that serum
from a non-immunized rabbit was used in place of the
primary antibodies. Specimens of prostate cancer with
ETAR-positive cancer tissue were used as a positive
control.
The ETAR immunoreactivity was evaluated according
to the percentage of stained cancer cells and the staining
intensity, which was classified into the following two
groups: positive, with more than 50% of tumor cells
having intense cytoplasmic staining, and negative,
representing other patterns of lower staining [31]. The
expression of ETAR was characterized as negative (−) orpositive (+) by one of the authors (H. Z. Zhang), who
had no prior knowledge of any of the clinical or radio-
logical data.
CXCR4 positivity was graded semi-quantitatively
according to Carcangiu’s method [32] as weak or absent
(total score ≤3) or strong (total score ≥4) by one of the
authors (H. Z. Zhang), without prior knowledge of the
clinicopathological features or the clinical follow-up data
of the patients.
Cell culture
Non-metastatic human 6-10B cells and metastatic 5-8F
cells [33] were obtained from the Department of Experi-
mental Research, Sun Yat-sen University Cancer Center.
The cells were cultured in RPMI 1640 medium
supplemented with 1% penicillin/streptomycin (Invitrogen)
and 10% FBS. All of the cells were maintained in 10-cm tis-
sue culture dishes in a 37°C incubator equilibrated with 5%
CO2 in humidified air.
Flow cytometry
Initially, the 6-10B cells were serum-starved for
24 hours and then stimulated with increasing concen-
trations (0, 0.1, 1, 10, and 100 nM) of ET-1 (Sigma) for
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The cells were then grown to subconfluence, detached
with cold Dulbecco’s PBS (5 mmol/L EDTA), and
washed with fluorescence-activated cell-sorting buffer
(5 mmol/L EDTA, 0.1% NaN3, and 1% FCS in
Dulbecco’s PBS). After incubation with a monoclonal
antibody against human CXCR4 (R&D Systems) for
30 minutes on ice, the cells were stained with an FITC-
labeled secondary antibody and examined for CXCR4
expression using flow cytometry (BD Biosciences).
Western blotting
Cell lysates from selected 6-10B and 5-8F clones were
prepared using standard procedures. The concentration
of total protein was determined using a BCA assay
(Pierce). Loading buffer was added to the protein (40 μg)
samples, which were boiled prior to resolution by SDS-
PAGE on 12% gels; the proteins were then transferred
onto PVDF membranes (Bio-Rad). The blots were
blocked for 2 hours with blocking reagent while shaking
and then incubated with a primary antibody against
CXCR4 (1:1000 dilution; Biolegend), ERK (1:1000 dilu-
tion; Santa Cruz), P-ERK (1:1000 dilution; Cell Signal-
ing), AKT (1:1000 dilution; Santa Cruz), P-AKT (1:1000
dilution; Santa Cruz), alpha tubulin (1:1000 dilution; Cell
Signaling), or GAPDH (1:1500 dilution; PTG). The blots
were washed and incubated for 2 hours with the corre-
sponding secondary antibodies (Dako). A rabbit anti-
mouse antibody was used at 1:6000 for CXCR4, and a
swine anti-rabbit antibody was used at 1:6000 for ERK,
P-ERK, AKT, P-AKT, and GAPDH. After washing, the
immunoreactive bands were visualized with Super Sig-
nal West Dura Extended Duration Substrate Enhanced
Chemiluminescent Substrate (Pierce Biotechnology).
Each assay was performed independently and in tripli-
cate. As a control for equal protein loading, immuno-
blotting for GAPDH or alpha tubulin were performed
on the membranes after stripping the previous antibodies.
The levels of CXCR4, ERK, P-ERK, AKT, and P-AKT were
normalized to that of GAPDH.
Real-time PCR
Prior to the PCR analysis, 6-10B cells were serum-
starved for 24 hours and then stimulated with increasing
concentrations (0, 0.1, 1, 10, and 100 nM) of ET-1
(Sigma) for 24 hours or with 10 nM ET-1 for the time
indicated. Total RNA was extracted from selected 6-10B
clones using TRIzol reagent (Life Technologies); a gen-
omic DNA removal kit (RNeasy Plus Mini Kit, Qiagen
GmbH) was used to remove any DNA from the sample.
The total RNA was then subjected to real-time RT-PCR
using an iCycler iQ Multicolor Real-Time PCR Detec-
tion System (Bio-Rad) with the iScript one-step RT-PCR
kit with SYBR Green (Bio-Rad). A melting curve analysiswas performed to evaluate the purity of the PCR prod-
ucts; triplicate samples were evaluated for each primer
set. The expression of CXCR4 relative to GAPDH
(a housekeeping control gene) was calculated using the
ΔCT method. The following CXCR4 primers were uti-
lized: sense, 5′-CCAACGTCAGTGAGGCAGAT-3′, and
antisense, 5′-GGCAGGATAAGGCCAACCAT-3′. The
following GAPDH primers were used: sense, 5′-AGCC
TCAAGATCATCAGC-3′, and antisense, 5′-GAGTCCT
TCCACGATACC-3′.
siRNA and transfections
The following siRNAs were purchased from Santa Cruz
Biotechnology, Inc.: siETAR (ETAR siRNA (h): sc-39960)
and siCXCR4 (CXCR-4 siRNA (h): sc-35421). The siRNA
transfection protocol is available online at http://datasheets.
scbt.com/siRNA_protocol.pdf.
Chemotaxis assays
Chemotaxis assays were performed using 48-well
chemotaxis chambers (Corning, USA). Aliquots of 27 to
29 μL of assay medium (RPMI 1640 containing 1% bo-
vine serum albumin and 30 mmol/L HEPES) with 100
nM SDF-1α (Merck) were placed in the lower wells of
the chamber, and a 200-μL cell suspension (5 × 104 cells/
mL) aliquot was placed in the upper wells. The 6-10B
cells were serum-starved and then stimulated with in-
creasing concentrations (0, 0.1, 1, 10, and 50 nM; Sigma)
of ET-1 for 12 hours with SDF-1α (100 nM) in the lower
chamber of the assay. ETAR or CXCR4 expression was
knocked down in the 5-8F cells, which were then stimu-
lated or not with ET-1 (10 nM). The upper and lower
wells were separated using a polycarbonate filter (10-μm
pore size; Osmonics), which was pre-coated with 50 μg/mL
collagen type I (Collaborative Biomedical Products).
After incubation at 37°C for 12 hours, the filter was re-
moved and stained, and the cells that had migrated
across the filter were counted under a light microscope
after coding the samples. The results were expressed as
the chemotaxis index, which represents the fold in-
crease in the number of migrated cells in response to
chemoattractants over spontaneous cell migration in
response to the control medium.
Statistical analysis
SPSS 13.0 was used for the statistical analysis. Survival
was calculated using the Kaplan-Meier method, and the
resulting curves were compared using the log-rank test.
Fisher’s exact test and the chi-square test were used to
analyze the association between two categorical vari-
ables. The Cox proportional hazard model was used to
perform a multivariate analysis of the risk factors for pa-
tient prognosis. P < 0.05 was considered to be statistically
significant.
Figure 1 (See legend on next page.)
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Figure 1 ETAR/CXCR4 expression levels and their prognostic value in undifferentiated NPC. A-F. Immunohistochemical staining pattern of ETAR/
CXCR4 expression. A. Positive staining for ETAR in prostate cancer tissue. B. Negative staining for ETAR in normal nasopharynx tissue. C. A case of
negative staining for ETAR. D. A case showing strong (≥50%) cytoplasmic staining for ETAR. E. A case showing strong cytoplasmic staining for CXCR4.
F. A case showing strong nuclear staining for CXCR4. Original magnification, × 200. G-N. Kaplan-Meier estimates of survival curves based on the ETAR/
CXCR4 expression levels of all 153 patients. G-J. Based on the ETAR expression levels. G. Overall survival, P= 0.004. H. Progression-free survival, P= 0.001.
I. Locoregional-relapse-free survival, P = 0.14. J. Distant-metastasis-free survival, P = 0.001. K-N. Based on the CXCR4 expression levels. K, Overall survival,
P< 0.0001. L, Progression-free survival, P< 0.0001. M. Locoregional-relapse-free survival, P= 0.024. N. Distant-metastasis-free survival, P< 0.0001.
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times, and representative results are shown. The signifi-
cance of the differences between various groups was
analyzed with Student’s t test or the chi-square test.
Results
The positive correlation between ETAR and CXCR4
expression in NPC tissue samples
Using prostate cancer tissue as a positive control (Figure 1A)
[31], ETAR expression was present in 73.9% (113/153)
of the tumor samples, whereas 14 cases (14/18, 77.8%)
of normal nasopharyngeal tissues were negative for
ETAR expression (Figure 1B). The intensity of staining
was variable among the samples, ranging from absent
or weak to strong (Figure 1C, D), and the ETAR immu-
noreactivity was mainly detected in the cytoplasm of
the carcinoma cells (Figure 1D). Strong CXCR4 expres-
sion was detected in 31.4% (48/153) of the cancer sam-
ples (Figure 1E, F), whereas the remaining 105 samples
displayed weak or absent CXCR4 staining. The ETAR
and CXCR4 expression levels were closely correlated
with each other: in the 48 NPC cases positive for the
expression of CXCR4, 46 (95.8%, P < 0.0001) were also
positive for ETAR expression (R = 0.338, P = 0.0001)
(Table 2).
The correlation between ETAR and CXCR4 and their
prognostic value
The 5-year OS, progression-free survival (PFS), locoregional
relapse-free survival (LRRFS), and DMFS rates in the
ETAR-positive patients were 56.6%, 45.9%, 76.5%, and
57.4%, respectively. The corresponding rates in the ETAR-
negative patients were 75.0%, 77%, 83.7%, and 90%, respect-
ively. With the exception of locoregional failure, all the
differences were statistically significant (Figure 1I). No cor-
relation was found between ETAR expression and theTable 2 Correlation between CXCR4 and ETAR
immunohistochemical expression
ETAR
CXCR4 No - + P value
- 105 38 67 <0.0001
+ 48 2 46 <0.0001
Total 153 40 113gender, age, T stage, N stage, or TNM clinical stage of the
patients (P > 0.05; Table 1).
Next, we analyzed the relationship between the
clinical outcome and CXCR4 expression levels. The 5-
year OS, PFS, LRRFS, and DMFS rates in the CXCR4-
positive patients were 39.6%, 30.6%, 69.1%, and 41.1%,
respectively; the corresponding rates were 71.4%,
64.9%, 82.4%, and 76.9%, respectively, in the CXCR4-
negative patients. All the differences were statistically
significant (Figure 1K-N). No correlation was found
between the CXCR4 expression levels and gender, age,
N stage, or TNM clinical stage of the patients (P > 0.05;
Table 1). However, CXCR4 expression did show a posi-
tive correlation with T stage (R = 0.1688, P = 0.038).
To adjust for prognostic factors, the following parame-
ters were included in the multivariate analysis using the
Cox proportional hazards model: gender (male vs. fe-
male), age (≤50 vs. >50 years), T stage (T1-2 vs. T3-4), N
stage (N0-1 vs. N2-3), clinical stage (stage I-II vs. stage
III-IV), ETAR expression (negative vs. positive), and
CXCR4 expression (weak/absent vs. strong ). A step-
wise forward procedure was used for the analyses. By
including the ETAR and CXCR4 expression levels sep-
arately in the Cox model, along with other variables,
the multivariate analysis showed that the expression of
ETAR was an independent prognostic factor for OS
(HR, 1.93; 95% CI, 1.10-3.38; P = 0.02), PFS (HR, 2.58;
95% CI, 1.28-5.22; P = 0.008), and DMFS (HR, 4.62;
95% CI, 1.66-2.86; P = 0.003) (Table 3) and that the ex-
pression of CXCR4 was an independent significant
prognostic factor for OS (HR, 2.78; 95% CI, 1.78-4.35;
P < 0.001), PFS (HR, 2.67; 95% CI, 1.67-4.28; P < 0.001),
and DMFS (HR, 3.35; 95% CI, 1.90-5.92; P < 0.001)
(Table 4). When ETAR and CXCR4 were included to-
gether in the Cox model, along with other variables,
the results showed that CXCR4 expression was an inde-
pendent prognostic factor for OS (HR, 2.78; 95% CI,
1.78-4.35; P < 0.001) and that both ETAR (HR, 2.12;
95% CI, 1.03-4.36; P = 0.04) and CXCR4 (HR, 2.30; 95%
CI, 1.42-3.72; P < 0.001) expression were independent
prognostic factors for PFS. For DMFS, N stage (HR, 1.96;
95% CI, 1.48-2.59; P < 0.001), ETAR expression (HR, 3.46;
95% CI, 1.22-9.84; P = 0.02), and CXCR4 expression
(HR, 2.52; 95% CI, 1.42-4.46; P = 0.002) were independent
prognostic factors. In contrast, clinical stage was the only
Table 3 Summary of the multivariate analysis of
prognostic factors in nasopharyngeal carcinoma
(Excluding CXCR4)
Clinical endpoint Prognosticator HR 95% CI P value
OS ETAR expression 1.93 1.11-3.38 0.02
UICC stage 1.54 1.19-2.01 0.001
N classification 1.42 1.12-1.80 0.003
Gender 0.57 0.34-0.93 0.026
Age 1.98 1.28-3.07 0.002
PFS ETAR expression 2.58 1.28-5.22 0.008
UICC stage 1.36 1.02-1.84 0.04
N classification 1.42 1.1-1.84 0.007
Gender 0.47 0.25-0.89 0.02
DMFS ETAR expression 4.62 1.66-12.86 0.003
N classification 1.92 1.46-2.54 <0.001
LRRFS UICC stage 1.76 1.22-2.54 0.002
CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, LRRFS
locoregional relapse-free survival, OS overall survival, PFS progression-free survival.
Table 5 Summary of the multivariate analysis of
prognostic factors in nasopharyngeal carcinoma
(Including ETAR and CXCR4)
Clinical endpoint Prognosticator HR 95% CI P value
OS CXCR4 Expression 2.78 1.78-4.35 <0.001
UICC Stage 1.51 1.15-1.98 0.003
N classification 1.47 1.16-1.88 0.001
Gender 0.48 0.29-0.80 0.004
Age 1.65 1.07-2.56 0.024
PFS CXCR4 Expression 2.30 1.42-3.72 <0.001
ETAR Expression 2.12 1.03-4.36 0.04
N classification 1.66 1.31-2.08 <0.001
Gender 0.38 0.21-0.72 0.003
DMFS CXCR4 expression 2.52 1.42-4.46 0.001
ETAR expression 3.46 1.22-9.84 0.02
N classification 1.96 1.48-2.59 <0.001
LRRFS UICC stage 1.76 1.22-2.54 0.002
CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, LRRFS
locoregional relapse-free survival, OS overall survival, PFS progression-free survival.
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(HR, 1.76; 95% CI, 1.22-2.54; P = 0.002) (Table 5).ET-1 induces CXCR4 mRNA and protein expression in 6-
10B NPC cells
We also investigated whether ETAR activation could in-
crease CXCR4 expression in human NPC cells using
real-time PCR for CXCR4 mRNA expression and west-
ern blotting and flow cytometric analysis for CXCR4
protein expression. The results showed that ET-1 in-
duced CXCR4 mRNA and protein expression in 6-10B
cells in a time- and concentration-dependent manner
(Figure 2A-F).Table 4 Summary of the multivariate analysis of
prognostic factors in nasopharyngeal carcinoma
(Excluding ETAR)
Clinical endpoint Prognosticator HR 95% CI P value
OS CXCR4 expression 2.78 1.78-4.35 <0.001
UICC stage 1.51 1.15-1.98 0.003
N classification 1.47 1.16-1.88 0.002
Gender 0.48 0.29-0.80 0.004
Age 1.65 1.07-2.56 0.02
PFS CXCR4 expression 2.67 1.67-4.28 <0.001
N classification 1.64 1.3-2.07 <0.001
Gender 0.36 0.20-0.69 0.00
DMFS CXCR4 expression 3.35 1.90-5.92 <0.001
N classification 1.88 1.42-2.49 <0.001
Gender 0.49 0.24-0.98 0.046
LRRFS UICC stage 1.76 1.22-2.54 0.002
CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, LRRFS
locoregional relapse-free survival, OS overall survival, PFS progression-free survival.siETAR reduces ETAR and CXCR4 protein expression and
attenuates ET-1 stimulation of CXCR4 expression in 5-8F
cells
The knockdown of ETAR protein expression by siETAR
reduced the expression of both ETAR and CXCR4 pro-
teins, and ET-1 could not increase CXCR4 expression
after ETAR knockdown in 5-8F cells (Figure 2G-I).
ET-1 in combination with SDF-1α promotes 6-10B and
5-8F NPC cell migration
A previous study showed that non-metastatic 6-10B
NPC cells do not migrate in response to SDF-1α, despite
the expression of CXCR4 by these cells [29]. Thus, the
effect of ET-1 on 6-10B cell migration was examined
using a Transwell assay. The results showed that 6-10B
cell migration was stimulated by ET-1 (0.1-100 nM) in
the presence of SDF-1α in a concentration-dependent
manner. However, no migration was observed when the
cells were treated in the absence of SDF-1α or with
SDF-1α alone (Figure 3). Therefore, ET-1 upregulated
the expression of functional CXCR4 and promoted the
migratory ability of the 6-10B cells. In contrast, ET-1 no
longer augmented CXCR4 expression in the 5-8F cells
after ETAR knockdown, and a chemotaxis assay showed
that ET-1 could not stimulate 5-8F cell migration, even
with the application of SDF-1α.
ET-1-induced CXCR4 expression in NPC cells is mainly
mediated through ETAR
In bladder cancer, ET-1 affects cell migration and invasion
through ETAR. Accordingly, ETAR inhibitors have been
suggested as potential therapeutic agents in advanced
Figure 2 (See legend on next page.)
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Figure 2 ET-1 induces CXCR4 mRNA and protein expression in 6-10B nasopharyngeal carcinoma cells in a time- and concentration-
dependent fashion (A-F). Initially, 6-10B cells were serum-starved for 24 hours and then stimulated with increasing concentrations (0, 0.1, 1, 10,
and 100 nM) of ET-1 for 24 hours or with 10 nM ET-1 for the indicated time. Total RNA was extracted and analyzed using real-time PCR for CXCR4
mRNA expression. Primers for GAPDH mRNA were used as a loading control (A, B). Whole-cell lysates were prepared, and CXCR4 levels were
analyzed by western blotting (C, D) and flow cytometry (E, F). As an internal control, the membranes were reprobed with a specific anti-GAPDH
antibody. CXCR4 induction was maximal in response to 10 nM ET-1 following a 24-hour exposure. Higher concentrations of ET-1 did not induce
further CXCR4 expression. CXCR4 expression increased within 1 hour and remained high at 48 hours. siETAR reduced ETAR and CXCR4 protein
expression and attenuated the ET-1-induced stimulation of CXCR4 expression in 5-8F cells (G-I). siRNA transfection was performed per the
protocol. Thirty-six hours after transfection, the cells were harvested, whole-cell lysates were prepared, and the CXCR4 and/or ETAR levels were
analyzed by western blotting. α-tubulin was used as internal control.NC is a negative control with scrambled siRNA. Representative results from
one of three independent experiments are shown.
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present study, we clarified the mediator responsible for
ET-1-induced CXCR4 expression in NPC cells. ET-1
upregulated CXCR4 expression in the 5-8F cells, but
CXCR4 expression was downregulated after ETAR was
knocked down, and ET-1 could not stimulate CXCR4
expression after siETAR treatment (Figure 2I). Pretreat-
ment of the 6-10B cells for 2 hours with the ETAR
antagonist BQ123 (1 μM) markedly inhibited the
expression of CXCR4 protein induced by ET-1
(Figure 4A). These results indicated that ETAR was the
mediator of ET-1-induced CXCR4 expression.
ET-1 upregulates the expression of CXCR4 via the PI3K/
AKT and MAPK/ERK1/2 pathways
To explore the signaling mechanism responsible for
ET-1-upregulated CXCR4 expression, immunoblotting
was used to observe alterations in the levels of phos-
phorylated ERK and AKT after the pretreatment of 6-
10B cells with 10 nM ET-1. ERK phosphorylation began
at 1 minute after ET-1 treatment and reached its max-
imum in 5 minutes, though the level was significantly
reduced 30 minutes later (P < 0.05). AKT phosphoryl-
ation began at 1 minute after ET-1 treatment and
reached its maximum in 30 minutes; the level was sig-
nificantly reduced after 60 minutes (P < 0.05). These results
suggested that the ET-1-induced upregulation of CXCR4
expression in the NPC cell line 6-10B might be mediated
by the phosphorylation of ERK and AKT (Figure 4B).
Interestingly, total ERK did not change significantly during
the progression, whereas total AKT slightly increased.
To further investigate whether the ET-1-induced
upregulation of CXCR4 occurred through the PI3K/
mTOR signaling pathway, 6-10B cells were incubated in
the presence of the PI3K inhibitors LY294002 and
wortmannin and the mTOR inhibitor rapamycin prior to
the administration of ET-1. LY294002 (0, 5, 10, 25, 50,
and 100 μM), wortmannin (10 μM), or rapamycin
(50 μM) were added to pretreat the cells for 2 hours
prior to the addition of 10 nM ET-1 for 24 hours. The
results show that CXCR4 expression was significantly
enhanced after 24 hours when ET-1 was added in theabsence of these inhibitors; however, the CXCR4 pro-
tein level was decreased when ET-1 was added to the
cells after pretreatment with an inhibitor. Specifically,
LY294002 administration resulted in a dose-dependent
decrease in ET-1-induced CXCR4 expression. Thus,
ET-1 promoted the expression of CXCR4, whereas the
PI3K inhibitors LY294002 and wortmannin and the
mTOR inhibitor rapamycin inhibited the upregulation
of CXCR4 by ET-1 (P < 0.05) (Figure 4C). Specifically,
administration of the PI3K inhibitor LY294002 resulted
in a dose-dependent decrease in ET-1-induced CXCR4
expression (Figure 4D).
We also examined the role of the MAPK/ERK1/2 sig-
naling pathway in ET-1-induced CXCR4 upregulation.
The cells were pretreated with the MEK inhibitor U0126
(10 μM), the ERK1/ 2 inhibitor PD98059 (50 μM), or the
P38MAPK inhibitor SB203580 (30 μM) for 1 hour prior
to the administration of 10 nM ET-1 for 24 hours. The
results show that ET-1 treatment in the absence of in-
hibitor resulted in the upregulation of CXCR4 expres-
sion. However, ET-1 treatment following pretreatment of
the cells with one of these inhibitors resulted in a mild
decrease in CXCR4 expression (P < 0.05) (Figure 4E).
Based on these results, it appears that the MAPK/ERK1/
2 signaling pathway is a second pathway involved in ET-
1-induced CXCR4 upregulation in 6-10B cells.
Taken together, these data suggest that ET-1 activates
the PI3K/AKT/mTOR and MAPK/ERK1/2 signaling
pathways via ETAR and then upregulates CXCR4 ex-
pression in 6-10B NPC cells.
Discussion
Distant metastases are the most frequent cause of death
in patients with NPC. In our previous study [8], we dem-
onstrated that NPC patients had a high plasma level of
ET-1, which correlated positively with metastasis and
was an independent prognostic factor in these patients.
ABT-627, an antagonist of ETAR, can significantly in-
hibit the growth of NPC xenografts in nude mice, reduce
metastatic lesions in the lung, and enhance the sensitiv-
ity of the tumors to chemotherapy [9]. The present study
showed that ETAR overexpression was associated with
Figure 3 ET-1 pretreatment augments the chemotactic activity of SDF-1α in 6-10B and 5-8F nasopharyngeal carcinoma cells. A-B. The
migration of 6-10B cells in response to SDF-1α was measured using chemotaxis chambers. Initially, 6-10B cells were serum-starved and then
stimulated with increasing concentrations (0, 0.1, 1, 10, and 50 nM) of ET-1 for 12 hours, along with SDF-1α (100 nM), in the lower chamber. ET-1
stimulation together with SDF-1α in the lower chamber had an additive effect and produced a level of migration that was significantly higher
than the level induced by SDF-1α alone. C-D. After transfection with siETAR and siCXCR4, ET-1 and/or SDF-1α no longer augmented chemotaxis
in 5-8F cells. All panels show the mean ± SE of the migration index from at least three separate experiments, which were each performed in
triplicate (Student’s unpaired t test; **P < 0.001 compared to SDF-1α alone).
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Figure 4 The mechanism of ET-1-induced expression of CXCR4
in 6-10B nasopharyngeal carcinoma cells. A. The ET-1-induced
expression of CXCR4 in 6-10B nasopharyngeal carcinoma cells is
mainly mediated through ETAR. Initially, 6-10B cells were serum-
starved for 24 hours and pretreated with a selective ETAR
antagonist, BQ123, for 2 hours. The cells were then either left
unstimulated or stimulated with 10 nM ET-1 for 24 hours. The
CXCR4 and GAPDH levels of whole-cell extracts were determined by
western blotting. B-E. The ET-1-induced stimulation of CXCR4
expression was activated via the PI3K/AKT/mTOR or MAPK1/ERK1/2
signaling pathway in 6-10B nasopharyngeal carcinoma cells. B.
Initially, 6-10B cells were serum-starved and treated with 10 nM ET-1
for various times, as indicated. Equal volumes of whole-cell lysate
were analyzed by western blotting for AKT (phosphorylated on
serine 473; P-AKT), total AKT, ERK1/2 (phosphorylated at threonine
202 and tyrosine 204; P-ERK1/2), total ERK1/2, and anti-GAPDH
(loading control). C. Initially, 6–10 B cells were serum-starved and
pretreated with LY-294002 (50 μM), wortmannin (10 μM), or
rapamycin (50 μM) for 2 hours and then incubated in the presence
of ET-1 (10 nM) for 24 hours. The CXCR4 levels were then analyzed
by western blotting. D. The dose-dependent effects of LY-294002 on
CXCR4 expression were evaluated in the presence of ET-1 (10 nM)
for 24 hours. E. Initially, 6–10 B cells were serum-starved and
pretreated with U0126 (10 μM), PD-98059 (50 μM), or SB203580
(30 μM) for 2 hours and then incubated in the presence of ET-1
(10 nM) for 24 hours. The CXCR4 levels were then analyzed by
western blotting. ET-1 stimulation activated the AKT and MAPK
signaling pathways, whereas blocking the PI3K/AKT or MAPK signal
prevented ET-1-induced CXCR4 expression. Representative results
from one of three independent experiments are shown.
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sults of others [27,28]. The ET-1/ETAR pathway regulates
tumor invasion and metastasis in many processes, includ-
ing adherence, mobility, the epithelial-mesenchymal tran-
sition (EMT), the secretion of degradation enzymes,
angiogenesis, bone deposition in bone metastasis, and the
formation of lymph vessels [35-37].
The present study showed that CXCR4 overexpression
was associated with distant metastasis in NPC patients.
In 2005, Hu et al. [28] were the first to demonstrate that
the CXCL12/CXCR4 axis plays a pivotal role in NPC
spread and specific organ metastasis, providing an im-
portant clue regarding the mechanisms involved in NPC
metastasis. Indeed, CXCR4 has been reported to be a
prognostic marker in various types of cancer, such as
acute myelogenous leukemia [38] and breast carcinoma
[39]. The specific expression of chemokines and their re-
ceptors is an important process in malignant tumor cells
that are prone to metastasize to remote organs. Balkwill
[40] reviewed studies demonstrating that malignant cells
from different types of cancer express CXCR4 and inter-
act with its ligand, SDF-1, indicating the critical role that
the SDF-1/CXCR4 pathway plays in tumor metastasis.
SDF-1 (also known as CXCL12) is a chemotactic protein
secreted by bone marrow stromal, mesothelial, and epi-
thelial cells. CXCR4 is the only known receptor for SDF-
1 and has a high affinity for this chemokine. The binding
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through several divergent pathways, initiating signals re-
lated to chemotaxis, cell survival and/or proliferation, in-
creased intracellular calcium, and gene transcription.
The CXCL12/CXCR4 axis is involved in tumor progres-
sion, angiogenesis, metastasis, and survival [41], and
promising results in preclinical tumor models indicate
that CXCR4 antagonists may have antitumor activity in
patients with various malignancies [42]. Smith et al. [43]
found that inhibiting CXCR4 with RNAi or the specific
antagonist AMD3100 substantially delayed the growth of
4 T1 breast cancer cells in the lungs of BALB/c mice.
These results extend the potential therapeutic applica-
tions of CXCR4 inhibitors to the treatment of both pri-
mary and metastatic breast cancer.
In the present study, we evaluated the expression of
ETAR and CXCR4 in NPC using immunohistochemistry.
To the best of our knowledge, we are the first to show
that ETAR expression is closely associated with CXCR4
expression in patients with NPC. As both ETAR expres-
sion and strong CXCR4 expression are associated with
unfavorable PFS and DMFS, it is interesting to evaluate
the relationship between ETAR and CXCR4 expression.
We speculated that there may be crosstalk between the
ET-1/ETAR and SDF-1α/CXCR4 pathways, and our
study indicated that the expression levels of ETAR and
CXCR4 were positively correlated. In the 48 NPC cases
positive for the expression of CXCR4, 95.8% also
exhibited ETAR expression, and our experimental study
also showed that ETAR activation increases functional
CXCR4 expression in 6-10B and 5-8F NPC cells. Both
the 5-8F and 6-10B cell lines are sub-clones of the NPC
cell line SUNE1 [33]: the 5-8F cell line has the potential
for high tumorigenesis and high metastasis, whereas the
6-10B cell line has the potential for tumorigenesis but
cannot metastasize. Qiu et al. [44] found that the expres-
sion level of CXCR4 is higher in 5-8F than in 6-10B
cells, and another study has shown that the 6-10B cell
line expresses CXCR4 but that the receptor is
inactivated [28]. It was also found that the ability of 5-8F
cells to proliferate and migrate increased after SDF-1α
stimulation, though no significant changes occurred in
the 6-10B cell line [28]. In the present study, we found
that pretreatment with ET-1 augments the chemotactic
activity of SDF-1α in the 6-10B NPC cell line via the
upregulation of the expression of functional CXCR4.
Our results suggested that the ET-1/ETAR pathway may
play an important role in CXCR4 expression in NPC.
Our results also revealed an association between ETAR
and CXCR4 expression, though the multivariate analyses
showed that the two expression levels are independent
of each other. However, it should be noted that we ap-
plied multivariate analyses to prognostic research and
that the factors that have an effect on prognosis are verycomplicated. For example, ET-1/ETAR may also pro-
mote cancer metastasis by regulating VEGF [45,46],
matrix metalloproteinase [47,48], hypoxia-inducible
factor-1alpha (HIF-1α) [49], and the epithelial-to-mesen-
chymal transition [50]. Thus, the association between
ETAR and CXCR4 that we revealed based on clinical
data only shows that the receptors are correlated in
quantity.
The present study showed that ET-1 induced CXCR4
expression by activating the PI3K/AKT/mTOR and/or
MAPK/ERK1/2 signaling pathways. Our study also
showed that ET-1-induced CXCR4 expression could be
inhibited by an ETAR antagonist or an inhibitor of
PI3K/AKT/mTOR or MAPK/ERK1/2. In fact, CXCR4
can be regulated by many pathways. A study by Segawa
et al. [51] demonstrated that high levels of CXCR4 and
VEGF correlate with a poor prognosis in NPC patients,
and Bachelder et al. [52] demonstrated that VEGF pro-
motes breast cancer tumor cell invasion via the
upregulation of CXCR4 expression.
Many studies have revealed a close relationship be-
tween CXCR4 and the PI3K/Akt/mTOR or MEK/ERK
pathway. Kukreja et al. [53] reported that CXCL12
upregulates CXCR4 via activation of the MEK/ERK and
NF-kB pathways in prostate cancer cells. In hepatocyte
growth factor (HGF)-treated MCF-7 cells, Maroni et al.
[54] demonstrated that the DNA binding of Ets1, acti-
vated by the MAPK/ERK1/2 transduction pathway, and
the DNA binding of NF-kB played a critical role in
CXCR4 transcription and protein induction and en-
hanced the invasion and migration ability of the breast
cancer cells. Phillips et al. [55] demonstrated that EGF
and hypoxia upregulate CXCR4 via the PI3K/AKT/
mTOR pathway and the activation of HIF-1α in NSCLC.
Lastly, Yu et al. [56] demonstrated that CXCR4 induces
MMP-9 and MMP-13 expression and promotes the in-
vasion ability of oral squamous carcinoma via the ERK
pathway.
Collectively, our observations revealed that ETAR and
CXCR4 are important molecules involved in the spread
and progression of NPC cells. ETAR activation promoted
NPC migration and was associated with a poor prognosis
via a mechanism that involves, at least in part, increasing
functional CXCR4 expression. Drugs targeting the
endothelin axis, such as the potent ETAR antagonist
atrasentan (ABT-627), have been studied in large clinical
trials and appear to have an impact on disease progression
and morbidity [57]. Several inhibitors/antagonists (e.g.,
T140, AMD3100) have recently been generated and theor-
etically may block direct interactions between CXCR4 and
CXCL12. Because of the critical role that the CXCL12/
CXCR4 axis plays in HIV infection and cancer metastasis,
it has served as an important target in the development of
antitumoral and anti-HIV-1 therapies [58]. Targeting
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therapy for preventing the metastasis of NPC. Hence, our
findings may be useful in the future development of novel
strategies for targeting NPC tumor metastasis.
Conclusion
Our study revealed that elevated ETAR and CXCR4 ex-
pression is correlated with distant metastasis and poor
survival in NPC patients and can serve as an independ-
ent prognostic factor in NPC patients. Thus, ETAR and
CXCR4 may be useful predictors of NPC prognosis. ET-
1 promoted NPC cell motility by elevating the level of
functional CXCR4 through the activation of the PI3K/
AKT/mTOR and/or MAPK/ERK1/2 signaling pathways.
ET-1 may play an important role in regulating CXCR4
expression in NPC cells; however, the mechanisms
underlying how ET-1 regulates CXCR4 are complex and
warrant further study.
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